| Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ... New England Journal of Medicine 373 (17), 1627-1639, 2015 | 9782 | 2015 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1671 | 2015 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1598 | 2019 |
| Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ... The Lancet 387 (10026), 1415-1426, 2016 | 954 | 2016 |
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study SHI Ou, JS Ahn, L De Petris, R Govindan, JCH Yang, B Hughes, H Lena, ... Journal of clinical oncology 34 (7), 661-668, 2016 | 716 | 2016 |
| Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non–small-cell lung cancer: Groupe Lyon-Saint-Etienne … P Fournel, G Robinet, P Thomas, PJ Souquet, H Léna, A Vergnenégre, ... Journal of clinical oncology 23 (25), 5910-5917, 2005 | 693 | 2005 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 553 | 2018 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 457 | 2021 |
| Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort J Mazières, G Zalcman, L Crinò, P Biondani, F Barlesi, T Filleron, ... Journal of clinical oncology 33 (9), 992-999, 2015 | 420 | 2015 |
| Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non–small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study R Corre, L Greillier, H Le Caër, C Audigier-Valette, N Baize, H Bérard, ... Journal of Clinical Oncology 34 (13), 1476-1483, 2016 | 394 | 2016 |
| Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small … G Robinet, P Thomas, JL Breton, H Lena, S Gouva, G Dabouis, ... Annals of oncology 12 (1), 59-67, 2001 | 335 | 2001 |
| Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial E Quoix, R Ramlau, V Westeel, Z Papai, A Madroszyk, A Riviere, ... The lancet oncology 12 (12), 1125-1133, 2011 | 329 | 2011 |
| Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease S Molet, C Belleguic, H Lena, N Germain, CP Bertrand, SD Shapiro, ... Inflammation Research 54, 31-36, 2005 | 326 | 2005 |
| Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction … M Pérol, C Chouaid, D Pérol, F Barlési, R Gervais, V Westeel, J Crequit, ... Journal of Clinical Oncology 30 (28), 3516-3524, 2012 | 282 | 2012 |
| Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial … F Barlesi, R Gervais, H Lena, J Hureaux, H Berard, D Paillotin, S Bota, ... Annals of oncology 22 (11), 2466-2470, 2011 | 277 | 2011 |
| Bevacizumab in patients with nonsquamous non–small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study B Besse, S Le Moulec, J Mazières, H Senellart, F Barlesi, C Chouaid, ... Clinical Cancer Research 21 (8), 1896-1903, 2015 | 245 | 2015 |
| A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer R Ramlau, E Quoix, J Rolski, M Pless, H Lena, E Lévy, M Krzakowski, ... Journal of Thoracic Oncology 3 (7), 735-744, 2008 | 238 | 2008 |
| TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo … E Quoix, H Lena, G Losonczy, F Forget, C Chouaid, Z Papai, R Gervais, ... The Lancet Oncology 17 (2), 212-223, 2016 | 210 | 2016 |
| Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial AJ de Langen, ML Johnson, J Mazieres, AMC Dingemans, G Mountzios, ... The Lancet 401 (10378), 733-746, 2023 | 189 | 2023 |
| Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01) C Chouaid, C Dujon, P Do, I Monnet, A Madroszyk, H Le Caer, JB Auliac, ... Lung cancer 86 (2), 170-173, 2014 | 185 | 2014 |
